To investigate the diagnostic performance of Femtosecond Laser Label-Free Imaging combined with artificial intelligence for predicting high-risk pathological features in lung cancer
Pulmonary nodules detected by clinical imaging with an indication for surgical resection.
Patient agrees to and is planned for pulmonary (partial) resection.
Resected specimens are suitable for FLI imaging.
Written informed consent obtained from the patient or legal representative.
Insufficient sample.
Specimen with crushing, contamination, or improper preservation, precluding valid imaging as judged by the investigator.
Inability to obtain matched pathology results corresponding to FLI images.
Inability to obtain final pathological diagnosis.
Lung cancer patients undergoing pulmonary resection.
Cohort
Prospective
Femtosecond Laser Label-Free Imaging Combined with Artificial Intelligence.
Diagnostic testFemtosecond Laser Label-Free Imaging Combined with Artificial Intelligence. The diagnostic results will be blinded to both the physicians (including all clinicians involved in the patient's diagnostic and treatment process, such as surgeons and pathologists) and the patient, and the diagnostic results will NOT affect the original treatment plan.
The primary endpoint is the accuracy of the FLI combined with the AI model in predicting regional lymph node metastasis status in lung cancer, evaluated using postoperative pathology results as the reference standard.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
